Intellectus Partners LLC Has $698,000 Stock Position in Merck & Co., Inc. $MRK

Intellectus Partners LLC lowered its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 26.4% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 8,729 shares of the company’s stock after selling 3,137 shares during the period. Intellectus Partners LLC’s holdings in Merck & Co., Inc. were worth $698,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Legend Financial Advisors Inc. acquired a new position in shares of Merck & Co., Inc. during the 2nd quarter worth $25,000. CBIZ Investment Advisory Services LLC grew its position in Merck & Co., Inc. by 141.7% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock worth $34,000 after acquiring an additional 221 shares during the last quarter. Fiduciary Wealth Partners LLC bought a new stake in Merck & Co., Inc. during the 1st quarter worth $48,000. MJT & Associates Financial Advisory Group Inc. bought a new stake in Merck & Co., Inc. during the 1st quarter worth $48,000. Finally, Mountain Hill Investment Partners Corp. bought a new stake in Merck & Co., Inc. during the 2nd quarter worth $43,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on MRK. Weiss Ratings restated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research report on Wednesday, October 8th. Citigroup began coverage on Merck & Co., Inc. in a research report on Monday, October 13th. They set a “neutral” rating and a $95.00 price objective on the stock. Berenberg Bank lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $100.00 to $90.00 in a research report on Wednesday, September 17th. Morgan Stanley boosted their price objective on Merck & Co., Inc. from $98.00 to $100.00 and gave the stock an “equal weight” rating in a research report on Monday. Finally, Wells Fargo & Company reduced their price objective on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $104.47.

Merck & Co., Inc. Trading Down 4.0%

NYSE MRK opened at $82.51 on Tuesday. The business’s 50-day moving average price is $84.51 and its two-hundred day moving average price is $81.89. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $105.07. The firm has a market capitalization of $206.09 billion, a PE ratio of 12.71, a price-to-earnings-growth ratio of 0.95 and a beta of 0.37. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, October 30th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.36 by $0.22. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The firm had revenue of $17.28 billion for the quarter, compared to analyst estimates of $17 billion. During the same quarter in the previous year, the company posted $1.57 EPS. The business’s revenue was up 3.7% on a year-over-year basis. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. On average, analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current year.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.